Despite Flat Q2, Sanofi Foresees Growth In H2, Fuelled by IO And Rare Blood Units
Executive Summary
CEO also says there's still room for more M&A, and that Sanofi is a virtual paragon of US pricing restraint that rivals can learn from.
You may also be interested in...
Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...
Executive All-Change: Bayer's Weinand To Join Sanofi, While Sanofi's Oelrich To Take His Place At Bayer
A head-spinning change of executives in Europe's leading pharmaceutical companies will see a new head of pharmaceuticals at Bayer and the former incumbent fetching up at Sanofi in the US.
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Sanofi and Regeneron’s Praluent could draw even with Amgen’s US Repatha in approved FDA indications in 2019. While the injectable PCSK9 inhibitors battle for payers and prescribers, Esperion is readying its oral bempedoic acid to join the lipid-lowering fray – and strategizing towards what could be the first statin intolerance indication.